TITLE

301 SSR149744, a new antiarrhythmic drug, prevents experimental induced atrial fibrillation

AUTHOR(S)
Cosnier-pucheu, S.; Roccon, A.; Rizzoli, G.; Gayraud, R.; Guiraudou, P.; Briand, D.; Roque, C.; Gautier, P.; Herbert, J.M.; Nisato, D.
PUB. DATE
June 2004
SOURCE
European Journal of Heart Failure. Supplements;Jun2004, Vol. 2 Issue 1, p53
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "SSR149744, a New Antiarrhythmic Drug, Prevents Experimental Induced Atrial Fibrillation," by A. Roccon and colleagues is presented.
ACCESSION #
13022322

 

Related Articles

  • Investigation of the interaction between flecainide and hERG potassium channels, through the use of flecainide analogues. Melgari, D.; El Harchi, A.; Dempsey, C. E.; Hancox, J. C. // Proceedings of the Physiological Society;2013, p441P 

    Flecainide is a Class Ic (Na+ channel blocking) antiarrhythmic drug widely use in clinical treatment of atrial fibrillation that has been associated with an increased risk of arrhythmic events in post-myocardial infarction patients (Echt et al., 1991). In addition to its Na+ channel blocking...

  • When should we discontinue antiarrhythmic therapy for atrial fibrillation after abdominal surgery? Pagano, Gennaro; Leosco, Dario; Ferrara, Nicola; Rocco, Nicola; Rispoli, Corrado; Iannone, Loredana; Testa, Serena; Compagna, Rita; Accurso, Antonello; Amato, Bruno // BMC Surgery;2013, Vol. 13 Issue Suppl 1, p1 

    An abstract of the article "When should we discontinue antiarrhythmic therapy for atrial fibrillation after abdominal surgery?" by Gennaro Pagano, Dario Leosco, Nicola Ferrara, Nicola Rocco, Corrado Rispoli, Loredana Iannone, Serena Testa, and Rita Compagna is presented.

  • No difference after ablation found in patients treated with antiarrhythmic drugs.  // Cardiology Today;May2011, Vol. 14 Issue 5, p17 

    This article discusses a clinical trial on atrial fibrillation in patients treated with antiarrhythmic drugs.

  • Antiarrhythmic for atrial fibrillation and flutter.  // Modern Medicine;Mar96, Vol. 64 Issue 3, p33 

    Reports on the marketing approval given Ibutilide fumarate, an antiarrhythmic drug for atrial fibrillation or atrial flutter. Duration of potency; Side effects.

  • Antiarrhythmic drug therapy in treating AF. McBride, Brian F. // Cardiology Today;Dec2009, Vol. 12 Issue 12, p9 

    The article discusses the use of antiarrhythmic drug therapy in patients with atrial fibrillation in the U.S.

  • Novel antiarrhythmic reduces recurrences of atrial fibrillation.  // Formulary;Jan1999, Vol. 34 Issue 1, p76 

    States that the investigational class III antiarrhythmic azimilide reduces symptom recurrences of atrial fibrillation. Mechanism by which the drug acts in the body; Dosage of administration; Median time to the first symptomatic recurrence of atrial fibrillation in patients taking azimilide.

  • Dronedarone effective for treatment of AF in different patient populations.  // Cardiology Today;Jul2009, Vol. 12 Issue 7, p15 

    The article discusses a study on the effectiveness of dronedarone, a drug under development for the indication of cardiac arrhythmias, in treating atrial fibrillation (AF).

  • Ibutilide for AF. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p17 

    Reports that Ibulitide, a class III antiarrhythmic agent, can also convert atrial fibrillation or flutter of recent onset to sinus rhythm. Administration of the agent.

  • Mortality rates from primary therapies for AF. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p17 

    Reports the development of recurrent atrial fibrillation (AF) after cardioversion to sinus rhythm even with antiarrhythmic therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics